These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9336352)

  • 1. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.
    Rahman ZU; Frye DK; Buzdar AU; Smith TL; Asmar L; Champlin RE; Hortobagyi GN
    J Clin Oncol; 1997 Oct; 15(10):3171-7. PubMed ID: 9336352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer.
    García-Carbonero R; Hidalgo M; Paz-Ares L; Calzas J; Gómez H; Guerra JA; Hitt R; Hornedo J; Colomer R; Cortés-Funes H
    J Clin Oncol; 1997 Oct; 15(10):3178-84. PubMed ID: 9336353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
    Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
    J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
    Schmid P; Schippinger W; Nitsch T; Huebner G; Heilmann V; Schultze W; Hausmaninger H; Wischnewsky M; Possinger K
    J Clin Oncol; 2005 Jan; 23(3):432-40. PubMed ID: 15659490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
    Bewick M; Chadderton T; Conlon M; Lafrenie R; Morris D; Stewart D; Glück S
    Bone Marrow Transplant; 1999 Aug; 24(4):377-84. PubMed ID: 10467326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.
    Somlo G; Doroshow JH; Forman SJ; Odom-Maryon T; Lee J; Chow W; Hamasaki V; Leong L; Morgan R; Margolin K; Raschko J; Shibata S; Tetef M; Yen Y; Simpson J; Molina A
    J Clin Oncol; 1997 Aug; 15(8):2882-93. PubMed ID: 9256132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
    Bearman SI; Overmoyer BA; Bolwell BJ; Taylor CW; Shpall EJ; Cagnoni PJ; Mechling BE; Ronk B; Barón AE; Purdy MH; Ross M; Jones RB
    Bone Marrow Transplant; 1997 Dec; 20(11):931-7. PubMed ID: 9422471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
    Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference.
    Rahman ZU; Frye DK; Smith TL; Asmar L; Theriault RL; Buzdar AU; Hortobagyi GN
    Cancer; 1999 Jan; 85(1):104-11. PubMed ID: 9921981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
    Biganzoli L; Cufer T; Bruning P; Coleman R; Duchateau L; Calvert AH; Gamucci T; Twelves C; Fargeot P; Epelbaum R; Lohrisch C; Piccart MJ
    J Clin Oncol; 2002 Jul; 20(14):3114-21. PubMed ID: 12118025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
    Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
    BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
    Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
    Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
    J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer.
    Schneeweiss A; Hensel M; Goerner R; Khbeis T; Hohaus S; Egerer G; Solomayer E; Haas R; Grischke EM; Bastert G; Ho AD
    Stem Cells; 2001; 19(2):151-60. PubMed ID: 11239170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.
    Boye K; Del Prever AB; Eriksson M; Saeter G; Tienghi A; Lindholm P; Fagioli F; Skjeldal S; Ferrari S; Hall KS
    Pediatr Blood Cancer; 2014 May; 61(5):840-5. PubMed ID: 24254749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
    Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
    Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
    Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
    J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
    Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
    J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue.
    Lind PA; Marks LB; Jamieson TA; Carter DL; Vredenburgh JJ; Folz RJ; Prosnitz LR
    Cancer; 2002 Jun; 94(11):2821-9. PubMed ID: 12115368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection.
    Montemurro F; Rondón G; Munsell M; Smith TL; Donato ML; Gajewski JL; Rahman ZU; Buzdar AU; Champlin RE; Ueno NT
    Biol Blood Marrow Transplant; 2003 May; 9(5):330-40. PubMed ID: 12766883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.